Dlk/ZIP kinase is a serine/threonine kinase highly homologous to DAP kinase. We have reported that HeLa ZIP kinase (hZIPK) phosphorylated the regulatory light chain of myosin II (MRLC) at both Ser19 and Thr18 in vitro. In this study, we demonstrate that hZIPK also induces the diphosphorylation of MRLC in nonmuscle cells. Peptide mapping revealed that transient transfection of hZIPK into HeLa cells caused diphosphorylation of MRLC. In contrast, transfection of the kinase inactive mutant of hZIPK did not induce any phosphorylation of MRLC. Using antibodies speci®c for mono-or diphosphorylated MRLC, we showed that diphosphorylated MRLC induced by the overexpression of hZIPK was concentrated in striking aggregates or bundles of actin ®laments in HeLa cells, while monophosphorylated MRLC showed no prominent localization to these aggregates. Overexpression of hZIPK also induced dramatic changes in cell shape and disruption of nuclear morphology reminiscent of changes during apoptosis. These eects of hZIPK were suppressed by the coexpression of a mutant MRLC where both phosphorylation sites were replaced with alanine, indicating that the changes in actin organization were a consequence of MRLC diphosphorylation. These results suggested that hZIPK plays a role in regulating actin organization and cell morphology in non-muscles and at least part of its eects are mediated through the diphosphorylation of MRLC. Oncogene (2001) 20, 8175 ± 8183.
Introduction
Phosphorylation of the regulatory light chain of myosin II (MRLC) is a necessary event for the initiation of contraction in smooth muscle cells (Sellers and Adelstein, 1987) . The primary site of phosphorylation by myosin light chain kinase (MLCK) is located at Ser19. Monophosphorylation at this site is sucient to stimulate actin-activated myosin II MgATPase and the contraction of smooth muscle (Sellers et al., 1985; Ikebe and Hartshorne, 1985) . Phosphorylation of MRLC at Thr18 in addition to Ser19 (referred to as diphosphorylation (Murata-Hori et al., 1999) ) can be induced by high concentrations of MLCK in vitro (Ikebe et al., 1986) . It is well documented that diphosphorylated MRLC is more eective than monophosphorylated MRLC in the enhancement of actinactivated MgATPase of myosin II and in promoting the assembly of myosin II ®laments (Ikebe et al., 1988) .
Phosphorylation of MRLC is believed to play a similar role in the function of myosin II in nonmuscle cells. For example, microinjection of the catalytic fragment of MLCK into the nonmuscle cells resulted in an increase of surface motility (Fishkind and Wang, 1991) . Recent studies using antibodies speci®c for monophosphorylated MRLC further suggested that monophosphorylation of MRLC in nonmuscle cells played a role in cell motility (Matsumura et al., 1998) and cytokinesis (Murata-Hori et al., 1998; Matsumura et al., 1998) . As for smooth muscle myosin II, diphosphorylation of nonmuscle MRLC in vitro caused a stronger enhancement of MgATPase activity and myosin ®laments assembly than did monophosphorylation (Ikebe, 1989) . In addition, during thrombinstimulated isometric contraction of human umbilical vein endothelial cells (HUVE), diphosphorylation of MRLC reached a higher level than did monophosphorylation (Goeckeler and Wysolmerski, 1995) , suggesting that diphosphorylation of MRLC may be associated with the development of strong tension in nonmuscle cells. However, it is still unclear whether MLCK alone is responsible for both monophosphorylation and diphosphorylation of MRLC, or additional kinase(s) might also be involved.
ZIP kinase (also termed as Dlk) is a serine/threonine kinase whose kinase domain is highly homologous to that of DAP kinase (death associated protein kinase) known as a mediator of gamma-interferon induced apoptosis . ZIP kinase itself has also been implicated in apoptosis (Kawai et al., 1998) . Unlike DAP kinase, ZIP kinase lacks the calmodulinregulatory domain and contains a leucine zipper domain at its C terminous (Kawai et al., 1998; KoÈ gel et al., 1998) . Previously we showed that HeLa ZIP kinase (hZIPK) can induce diphosphorylation of MRLC independently of Ca 2+ /calmodulin in vitro (MurataHori et al., 1999) . ZIP kinase derived from smooth muscle was also reported to induce Ca 2+ /calmodulinindependent diphosphorylation of MRLC and contraction of smooth muscle (Niiro and Ikebe, 2001 ). These observations suggest that ZIP kinase might play an important role in regulating smooth muscle and nonmuscle contractility through Ca 2+ /calmodulin independent diphosphorylation of MRLC.
The purpose of this study is to investigate if hZIPK can induce diphosphorylation of MRLC in nonmuscle cells, and, if so, how MRLC diphosphorylation aects actin organization and cell morphology. Using a speci®c antibody for diphosphorylated MRLC, we showed that hZIPK can indeed cause diphosphorylation of MRLC in nonmuscle cells. Moreover, like Dlk (KoÈ gel et al., 1999) , hZIPK induced the formation of thick bundles and aggregates of actin ®laments, which colocalized with a high concentration of diphosphorylated MRLC. Our data suggested that hZIPK plays a role in the reorganization of cytoskeleton through the induction of MRLC diphosphorylation.
Results

hZIPK induces diphosphorylation of MRLC
To determine whether MRLC is a reasonable substrate for hZIPK in vivo, we ®rst estimated the apparent kinetic constants for the phosphorylation reaction (Table 1) . Although the molecular activity (K cat ) of hZIPK was lower than that of MLCK, the K m value of hZIPK was lower than that of MLCK or Rho-kinase, indicating that hZIPK can more eciently phosphorylate MRLC than does MLCK or Rho-kinase.
Immunoblotting of cell lysates from both hZIPKand hZIPK K42A (a kinase negative mutant of hZIPK)-transfected cells with anti-Xpress antibody detected a single 52-kD band. When lysates of transfected cells were immunoprecipitated with antiXpress antibody and subjected to a MRLC kinase activity assay, only immunoprecipitates from hZIPK-, but not hZIPK K42A-transfected cells, were able to phosphorylate MRLC ( Figure 1A , lower panel). Twodimensional phosphopeptide mapping analyses revealed that the phosphorylation sites of MRLC by hZIPK were the same as those by a high concentration of MLCK ( Figure 1B) , which is known to phosphorylate MRLC at Thr18 and Ser19. A similar pattern of phosphorylation was observed when GST-fused hZIPK was used instead of immunoprecipitated hZIPK (Murata-Hori et al., 1999) . These results suggest that expressed hZIPK was capable of diphosphorylation of MRLC at both Ser19 and Thr18.
The antibody PP1 recognized specifically diphosphorylated MRLC in nonmuscle cells
To determine whether hZIPK induces diphosphorylation of MRLC in intact cells, we produced polyclonal antibodies PP1 against a synthetic diphosphorylated peptide, Lys-Arg-Pro-Gln-Arg-Ala-phospho Thr-phospho Ser-Asn-Val-Phe (12-22 on MRLC from chicken gizzard and HeLa cells). To check the speci®city of PP1, immunoblot analysis was performed with myosin II essential light chain (MELC), unphosphorylated MRLC, and MRLC phosphorylated by MLCK or (Figure 2A, a) . The phosphorylation sites of MRLC by PKC were located at Ser1/ Ser2 and Thr9 and were dierent from those by MLCK (Ikebe et al., 1987) . As shown in Figure 2A (a, lanes 2, 4 and 6), PP1 recognized only MRLC phosphorylated by MLCK. When immunoblot analysis was performed with unphosphorylated, monophosphorylated or diphosphorylated MRLC separated by glycerol PAGE (Figure 2A, b) , only a single band of diphosphorylated MRLC was detected by PP1 ( Figure  2A , b, lane 2). Furthermore, when PP1 was preincubated with nonphosphorylated, monophosphorylated or diphosphorylated peptide, only diphosphorylated peptide was able to quench the reactivity of PP1 (Figure 2A , b, lanes 3 ± 5), con®rming that PP1 only recognizes diphosphorylated MRLC.
We also carried out immunoblotting of the whole cell lysates from HeLa cells with PP1 ( Figure 2B ). PP1 reacted with two bands in the region of MRLC ( Figure  2B , b, lane 1). The reaction with both bands was enhanced when the lysate was incubated with exogenous MLCK ( Figure 2B , a, lane 3, arrows; and B, b, lane 2). These two bands were also recognized by the P1 antibody against monophosphorylated MRLC (Murata-Hori et al., 1998; Figure 2B , a, lane 4), and by the CS1 antibody ( Figure 2B , b, lane 3) against a consensus sequence (the residues 127 ± 140) of all the isoforms of MRLCs irrespective of the states of phosphorylation (Figure 2A , c). These observations suggest that the two immunoreactive bands represented two isoforms of MRLC in cultured cells (Goeckeler and Wysolmerski, 1995) . Figure 3B ). They colocalized well with total myosin II and bundles of actin ®laments known as stress ®bers ( Figure 3A,C) . Monophosphorylated MRLC showed a weaker, punctate reaction along the stress ®bers ( Figure 3D ± F) . These observations supported the notion that P1 and PP1 antibodies react dierentially with monophosphorylated and diphosphorylated MRLC in the cells. Figure  4B , arrows). These aggregates contained a high concentration of actin ®laments with radiating ®lament bundles, indicating that hZIPK also induced dynamic reorganization of actin ®laments ( Figure   4C , arrows). However, staining of hZIPK-transfected cells with P1 revealed no prominent localization to these aggregates ( Figure 4D ,E). In contrast, hZIPK K42A-transfected cells (Figure 5A, D) showed no apparent dierence from control cells when stained with PP1 ( Figure 5B ), P1 ( Figure 5E ) and phalloidin ( Figure 5C ,F). Consistent with a previous report that overexpression of ZIP kinase induced apoptosis (Kawai et al., 1998) , DAPI staining of hZIPK transfected cells showed a disrupted nuclear morphology ( Figure 6B, arrowheads) . Moreover, hZIPK induced an apparent collapse of the cell in overexpressing cells ( Figure 4A,D) , as seen typically during apoptosis, while hZIPK K42A induced no apparent change ( Figure 5A,D) .
To determine whether diphosphorylation of MRLC by hZIPK is responsible for the induction of actin reorganization, we cotransfected HeLa cells with hZIPK and a MRLC mutant, in which Thr18 and Ser19 were substituted with Ala making these sites non-phosphorylatable ( Figure 7) . Strikingly, more than 80% of the cells coexpressing this non-phosphorylatable MRLC with hZIPK showed no prominent aggregation of actin ®laments ( Figure 7D ± F and Figure 8 ). In contrast, large aggregates of actin ®laments were found in 60% of the cells coexpressing hZIPK and wild type MRLC ( Figure 7A ± C) . From these results, we conclude that the expression of hZIPK induces diphosphorylation of MRLC, which in turn lead to the bundling and organization of actin ®laments in nonmuscle cells. Transfected cells were also stained with anti-Xpress antibody (FITC, green) (D), P1 (Alexa 568, red) (E) and CPITC-phalloidin (blue) (F). Note that the large aggregates and thick ®lamentous structures were strongly stained by PP1 (B, arrows) but faintly by P1 (E) in hZIPK-transfected cells. Aggregates or thick bundles of diphosphorylated MRLC in B were also stained by CPITC-phalloidin in hZIPK-transfected cells (C, arrows), suggesting that diphosphorylated MRLC colocalized with the large actin bundles in these structures Figure 5 Kinase-inactive form of hZIPK cannot induce the phosphorylation of MRLC or the reorganization of actin ®laments in HeLa cells. HeLa cells were transiently transfected with Xpress-tagged hZIPK K42A and ®xed in the same manner as Figure 4 . Then, they were stained with anti-Xpress antibody (FITC, green) (A), PP1 (Alexa 568, red) (B) and CPITC-phalloidin (blue) (C). Transfected cells were also stained with anti-Xpress antibody (FITC, green) (D), P1 (Alexa 568, red) (E) and CPITC-phalloidin (blue) (F). No aggregates or thick bundles of actin ®laments were observed in hZIPK K42A-transfected cells
Discussion
Unlike mouse ZIP kinase (Kawai et al., 1998) and rat Dlk (KoÈ gel et al., 1998), which localizes in the nucleus, hZIPK appears to localize primarily in the cytoplasm. The C-terminal sequences of hZIPK was only weakly homologous to those of mouse ZIP kinase and rat Dlk, which included the important domains for binding to a transcription factor ATF4 (Kawai et al., 1998; Page et al., 1999) , and a modulator of transcription Par-4 (Page et al., 1999) . Truncation of the C-terminal domain of Dlk resulted in the failure to transport into the nuclei and in an increase in the rate of apoptosis (KoÈ gel et al., 1998) . Thus the dierence in C-terminal domain among these kinases may lead to distinct regulatory mechanisms, localization, and cellular functions.
We demonstrated that hZIPK eciently induces diphosphorylation of MRLC in vitro (Murata-Hori et al., 1998) and in vivo (this work). While MLCK is known to induce diphosphorylation of MRLC (Ikebe, 1989) , it requires a higher concentration than does hZIPK. In contrast, smooth muscle ZIP kinase was found to induce diphosphorylation of MRLC before saturating the monophosphorylation of MRLC (Niiro and Ikebe, 2001) , suggesting that hZIPK induced predominantly diphosphorylation of MRLC in nonmuscle cells. The ecient diphosphorylation, and its independence of Ca 2+ /calmodulin, suggest that hZIPK may play important physiological roles in nonstimulated cells, whereas MLCK may induce additional increases in myosin activities in response to Ca 2+ / calmodulin signals.
We showed that the diphosphorylated MRLC localized to a much higher degree along actin bundles in cultured REF cells than did monophosphorylated MRLC (Figure 3) . Furthermore, we showed that overexpression of hZIPK in HeLa cells induced the formation of striking aggregates and bundles of actin (D) showed the merged image of DAPI (B) and TRITC-phalloidin (C). Note the collapse of the cell shape (A) and disruption of the nuclear morphology (B, arrowheads) in hZIPK-transfected cells Figure 7 Non-phosphorylatable MRLC mutant inhibits diphosphorylation of MRLC and actin ®laments reorganization by hZIPK. HeLa cells transfected with both hZIPK and wild type MRLC (A ± C) or non-phosphorylatable MRLC mutant (D ± F) were ®xed and stained with anti-Xpress antibody (Alexa 488, green) (A and D), anti-myc antibody (Alexa 568, red) (B and E) and CPITC-phalloidin (blue) (C and F). While large aggregates of actin ®laments (C) were induced by cotransfection of hZIPK and wild type MRLC, coexpression of hZIPK and non-phosphorylatable MRLC mutant inhibited the formation of these structures ®laments, which contained a high concentration of diphosphorylated but not monophosphorylated MRLC. Because diphosphorylation of MRLC eectively enhances the actin-activated MgATPase activity of myosin II (Ikebe, 1989) , diphosphorylated MRLC may play a more important role than monophosphorylated MRLC in regulating cell shape in nonmuscle cells. Such diphosphorylation-induced contraction may be responsible for the formation of the aggregates of actin ®laments. It is also consistent with the association of ZIP kinase with actin ®lamentous structures in the smooth muscle cells (Niiro and Ikebe, 2001 ).
Since hZIPK is likely to have additional substrates, it is important to determine that the diphosphorylation of MRLC is responsible for the reorganization of actin ®laments. This notion is strongly supported by the coexpression of a non-phosphorylatable MRLC with hZIPK, which eectively inhibited both the increase in MRLC diphosphorylation and the formation of actin aggregates. In addition, while rat Dlk is known to phosphorylate primarily nuclear substrates (KoÈ gel et al., 1999) , the cytoplasmic localization of hZIPK makes it unlikely that the observed eects were due to the phosphorylation of nuclear proteins.
In addition to direct diphosphorylation of MRLC, hZIPK may also exert its eects through the regulation of phosphatases. This notion is suggested by a recent report that identi®ed a smooth muscle myosin light chain phosphatase-associated kinase as a ZIP-like kinase (MacDonald et al., 2001) . This newly identi®ed kinase was shown to phosphorylate an inhibitory site on the regulatory myosin phosphatase targeting subunit (MYPT1), inducing the inhibition of myosin phosphatase activity. Since the inhibition of MYPT1 activity is known to induce actin ®lament reorganization (Kawano et al., 1999; Totsukawa et al., 2000) , this provides an alternative pathway for hZIPK to induce actin ®lament reorganization.
hZIPK may also play a role in apoptosis through diphosphorylation of MRLC. The level of diphosphorylation of MRLC has been found to increase signi®cantly during Fas-or TNF-triggered apoptosis (Sebbagh et al., 2001; Petrache et al., 2001) , which lead to membrane blebbing as seen in apoptotic cells (Mills et al., 1998) . This apoptosis-induced increase in MRLC diphosphorylation was reduced by the Rho-kinase inhibitor Y-27632 or MLCK inhibitor ML-7, indicating that Rho-kinase and/or MLCK had been activated during apoptosis. As a speci®c inhibitor for hZIPK is not now available, however, we do not estimate the contribution of hZIPK for MRLC diphosphorylation during apoptosis. ATF4 has been reported to be one of the candidates that participates in the negative regulation of ZIP kinase, by binding to the leucine zipper domain of ZIP kinase and interfering with the homodimerization of the kinase (Kawai et al., 1998; Page et al., 1999) . To study the contribution of hZIPK with respect to other known mediators of MRLC diphosphorylation, we are now conducting cotransfection experiments of ATF4 and hZIPK into cells.
We have revealed that predominant diphosphorylation but not monophosphorylation of MRLC showed a disrupted nuclear morphology in hZIPK-transfected cells. It also was reported that coexpression of rat Dlk and a transcription factor Par-4 led to relocation of Dlk from the nucleus to the cytoplasm and the induction of apoptosis (Page et al., 1999) . Thus, hZIPK might provide a second mechanism for the diphosphorylation of MRLC in the cytoplasm at the onset of apoptosis.
Interestingly, Inbal et al. (1997) demonstrated the existence of inverse relationships between DAP kinase expression and the ability of carcinoma cells to metastasize to the lungs, suggesting that DAP kinase links the control of apoptosis to metastasis. Furthermore, several lines of experiments suggested that cell migration/invasion requires MRLC phosphorylation (Somlyo et al., 2000; Cho and Klemke, 2000) . Although the molecular mechanism of DAP kinase control in metastasis is unclear, these phenomena suggest that hZIPK also plays some roles in metastasis via MRLC phosphorylation.
Materials and methods
Materials
MLCK and MLCs from chicken gizzard were puri®ed according to the method described previously (Murata-Hori , 1998) . PKC puri®ed from rabbit brain was kindly provided by Drs K Mizuno and S Ohno (Yokohama City University, Yokohama, Japan). HeLa cells (RCB0007; similar to ATCC CCL2, HeLa) and rat embryo ®broblasts (REF) cells (RCB0165) were obtained from Riken Cell Bank (Tsukuba, Japan) and were grown as described previously (Murata-Hori et al., 1998) . Calmodulin, peptide inhibitor for protein kinase A (A kinase inhibitor) were purchased from Sigma. Butyrolactone I was from Aniti Research Products Ltd. The anti-Xpress monoclonal antibody (mAb) and the anti-myc polyclonal antibody were purchased from Invitrogen and Santa Cruz, respectively. Secondary antibodies of Alexa Fluor 568-goat anti-rabbit IgG (H+L) and Alexa Fluor 488-goat anti-mouse IgG (H+L) were from Molecular Probes. FITC-conjugated anti-mouse IgG(Fc) was from TAGO. Coumarin phenyl isothiocyanate (CPITC) labeled phalloidin and tetramethyl rhodamine isotyocyanate (TRITC) labeled phalloidin were from Sigma. 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) was from Nacalai Tesque. Anti-pan myosin antibody was from Amersham.
Plasmid construction
Full-length of hZIPK was isolated from a HeLa cDNA library (Murata-Hori et al., 1999) . A kinase-inactive mutant of hZIPK (termed as hZIPK K42A) and a non-phosphorylatable MRLC mutant were generated by site-directed mutagenesis using PCR. In hZIPK K42A, the critical lysine (K) at position 42 in the putative ATP binding site was mutated to alanine (A) (Hanks and Quinn, 1991) . Both cDNA fragments encoding hZIPK and hZIPK K42A were ampli®ed by PCR and subcloned into the frame with the N-terminal Xpress peptide of the pcDNA3.1/HisA vector (Invitrogen), respectively.
For non-phosphorylatable MRLC mutant, both serine 19 and threonine 18 of human MRLC2 (accession number; D82058) was substituted by alanine. Both wild type and nonphosphorylatable MRLC were subcloned into the frame with the C-terminal myc peptide of pcDNA3.1/Myc-HisA vector (Invitrogen), respectively.
Preparation of total cell lysates and immunoblotting
HeLa cells were grown to con¯uent levels on 14 large culture dishes (25625 cm, SUMILON) in Eagle's Minimal Essential Medium (MEM, Nissui) containing 10% FBS (INTERGEN). The cells were collected and washed three times with PBS containing 5 mM MgCl 2 , 0.2 mM EGTA and 1 mM PMSF. Cell pellets were homogenized with an equal volume of Triton/glycerol solution (0.1 M PIPES, pH 6.9, 5 mM MgCl 2 , 0.2 mM EGTA, 0.05% Triton X-100 and 4 M glycerol). The homogenates were then centrifuged at 100 000 g for 1 h at 48C and the supernatants were obtained. The supernatant was incubated with 0.1 mM calyculin A, 0.1 mM Okadaic acid, 250 mg/ml leupeptin, 1 mM PMSF, 1 mM butyrolactone I, 0.5 mM A kinase inhibitor, 2 mM MgCl 2 , 2 mM CaCl 2 , 20 mg/ ml calmodulin and 1 mM ATP with or without 150 mg/ml MLCK at 258C for 90 min. After incubation, Laemmli sample buer was added (Laemmli, 1970) . Each sample was separated on SDS ± PAGE and then blotted on polyvinylidene di¯uoride (PVDF) membranes (Immobilon, Millipore). Immunoblotting was performed as described elsewhere (Murata-Hori et al., 1998) .
Transfection and immunoprecipitation
HeLa cells were plated at a density of 10 4 cells per 3.5 cm dish with the coverglass and at a density of 10 5 cells per 10 cm dish for indirect immuno¯uorescence and immunoprecipitation studies, respectively. After culturing for 2 days, cells were transfected with one or two constructs by the application of Lipofectamine (Gibco BRL)-DNA complex. After 4 h incubation, MEM containing 10% FBS was added and the cells were cultured for an additional 14 h. For immunoprecipitation, 2.5610 6 transfected cells were washed twice with PBS (140 mM NaCl, 3 mM KCl, 1.5 mM KH 2 PO 4 and 8 mM Na 2 HPO 4 , pH 7.3) containing 0.2 mM EGTA, 5 mM MgCl 2 and 1 mM PMSF and then lysed with RIPA buer (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (10 mM leupeptin, 1 mM pepstatin A, 1 mM PMSF and 10 mM EGTA). The cell lysate was precleared with protein G-Sepharose beads (Amersham Pharmacia Biotech) for 1 h and then incubated with 0.4 mg anti-Xpress mAb for 1 h under constant rotation. Protein G-Sepharose beads were added into the lysate and incubated for an additional 1 h by rotation. The beads were washed twice with RIPA buer. Immunoprecipitants were eluted with Laemmli sample buer, subjected to SDS ± PAGE, transferred onto a PVDF membrane and immunoblotted.
Protein kinase assay and two-dimensional phosphopeptide mapping analysis
In order to calculate apparent kinetic constants for phosphorylation of MRLC by hZIPK, phosphorylation of MLCs by puri®ed GST-hZIPK (100 ng) was carried out in 20 ml of the reaction mixture (20 mM Tris-HCl, pH 8.0, 80 mM NaCl, 1.6 mM MgCl 2 , 0.9 mM [g-32 P]ATP) containing various amounts of MLCs at 258C. Phosphorylation of MLCs (0.06 mg/ml) by immunoprecipitated hZIPK was performed for 30 min at 258C with the reaction mixture (27 mM Tris-HCl, pH 8.0, 1 mM EGTA, 8 mM MgCl 2 , 10 mM NaCl, 10 mM DTT, 0.1 mM PMSF, 0.3 mg/ml leupeptin, 0.3 mg/ml pepstatin A, 0.5 mM calyculin A) containing 0.18 mM [g-32 P]ATP. Phosphorylation of MLCs by MLCK was performed as described previously (MurataHori et al., 1999) . Laemmli sample buer was added into the reaction mixture to terminate the reaction and samples were subjected to SDS ± PAGE. Radiolabeled bands were visualized with a Bio Imaging Analyzer BAS 2000 (Fuji). Twodimensional phosphopeptide mapping of 32 P-labeled MRLC were produced as described previously (Murata-Hori et al., 1999) , except for the use of a cellulose plate (Merck) instead of silica gel plate (Merck).
Preparation of affinity-purified antibodies P1 antisera against phosphorylated peptide Lys-Arg-Pro-GlnArg-Ala-Thr-phospho Ser-Asn-Val-Phe, which corresponded to monophosphorylated MRLC, have been prepared and characterized previously (Murata-Hori et al., 1998) . PP1 antisera against diphosphorylated peptide (Lys-Arg-Pro-GlnArg-Ala-phospho Thr-phospho Ser-Asn-Val-Phe), and CS1 antisera against the peptide Thr-Thr-Met-Glu-Asp-Arg-PheThr-Asp-Glu-Glu-Val-Asp-Glu corresponding to residues 127 ± 140 on HeLa MRLC, were prepared by Dr K Nakashima (Peptide Institute, Inc., Osaka, Japan). Brie¯y, Japanese white rabbits were immunized via a popliteal lymphonode, and bled 3 months after immunization by cardiac puncture. The antibodies P1, PP1 and CS1 were anity-puri®ed from the antisera, as described previously (Murata-Hori et al., 1998) . BSA was added to a neutralized eluent to a ®nal concentration of 0.5%.
Indirect immunofluorescence
Cells on cover slips were ®xed either for 10 min in 3.7% formaldehyde in PBS at room temperature. When the cells were ®xed with formaldehyde, they were made permeable by incubating them in 0.2% Triton X-100 in PBS for 15 min, and then washing them in PBS. After blocking with PBS containing 1% BSA, antibodies were applied directly to the coverslips. The coverslips were incubated for 1 h in a moist chamber and then washed for 30 min in several changes of PBS. The cells were then stained with secondary antibodies described above or CPITC-phalloidin, in a manner identical to that in the ®rst staining. After washing in PBS, coverslips were mounted onto a microscope slide with a drop of mounting medium for preserving¯uorescence (Immunon). Imaging was performed with Nikon ECLIPSE TE300 microscope. All images were acquired with digital CCD camera (ORCA, C4742-95-12, Hamamatsu Photonics) and processed with custom software.
Other procedures SDS ± PAGE and glycerol PAGE were carried out as described previously (Murata-Hori et al., 1998) .
